...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Phase 3 BETonMACE Trial is Now Completed. Cognition and CKD Sub-Study Results to be Announced Soon.

Free
Message: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019

Those are some pretty strong statements. First sub-title of news release is:

"Apabetalone treatment improves cognition in CVD patients with diabetes"

Then, they quote Dr. Cummings: 

"The effects seen in the BETonMACE trial for those with cognitive impairment are very promising and suggest that epigenetic modulators such as apabetalone may represent an important and novel approach to treatment of cognitive disorders"

Share
New Message
Please login to post a reply